However, a single use of TRAIL as an anti-cancer drug often produces insufficient clinical efficacy [26], and preclinical studies have shown that approximately half of the lung cancer cell lines are intrinsically resistant to the apoptotic activity of TRAIL receptor targeting therapy [27], including A549 cells. The gene discussed is TNFSF10; the disease is cancer.